BioMed Research International · 2014 · 46 citations · 43 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaTumor PathologyGastrointestinal Stromal TumorsImmunohistochemistryMolecular Classification Of TumorsTumor ClassificationTumor DifferentiationTumor MarkersDensityDiagnostic ImmunohistochemistryImmunohistochemistry AssaysKit SignalingMast Cell BiologyMast Cell DifferentiationMicrovascular Density
Canine cutaneous mast cell tumour (CMCT) is a c-Kit driven tumour sharing similar c-Kit aberrations found in human gastrointestinal stromal tumour. CMCT is classified into three forms: well- (G1), intermediately (G2) (more benign diseases), and poorly (G3) differentiated (malignant) forms. We assess a correlation between c-Kit status, grading, and angiogenesis in CMCTs to explore their potential significance in humans. C-Kit receptor (c-KitR) expression, microvascular density (MVD), and mast cell granulated and degranulated status density (MCGD and MCDD, resp.) were analyzed in 97 CMCTs, by means of histochemistry, immunohistochemistry double staining, and image analysis system. Data showed that predominantly diffuse cytoplasmic- and predominantly focal paranuclear- (Golgi-like) c-Kit protein (PDC-c-Kit and PFP-c-Kit, resp.) expression correlate with high MVD, G3 histopathological grade, and MCDD. Moreover, predominant cell membrane-c-KitR (PCM-c-KitR) expression status correlates with low MVD, G1-G2 histopathological grade, and MCGD. These findings underline the key role of c-Kit in the biopathology of canine MCTs, indicating a link between aberrant c-Kit expression, increased angiogenesis, and higher histopathological grade. CMCT seems to be a model to study contributions of c-Kit activated MCs in tumour angiogenesis and to evaluate the inhibition of MCs activation by means of c-Kit tyrosine kinase inhibitors, currently translated in humans.
43
Cheryl A. London, Phyllis B. Malpas, Stacey L. Wood-Follis et al. · Clinical Cancer Research · 2009 · 422 citations · Full text
Medicine, Oncology, Pharmacology +15
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Patrice Dubreuil, Sébastien Letard, Marco A. Ciufolini et al. · PLoS ONE · 2009 · 412 citations · Full text
Medicine, Oncology, Pharmacology +15
Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
K. Hahn, G. Oglivie, Todd Rusk et al. · Journal of Veterinary Internal Medicine · 2008 · 284 citations · Full text
Mast cells and tumor angiogenesis
David A. Kessler, Róbert Langer, Naomi A. Pless et al. · International Journal of Cancer · 1976 · 268 citations